## Intuitive Surgical (ISRG) — filing-driven deep dive (business, numbers, risks, governance) ### Quick “choose-your-own-adventure” menu (optional) Reply with a number anytime and I’ll extend that section further with more tables + excerpts: 1) **Unit economics / procedures / installed base** 2) **Margins & operating leverage** 3) **Capital allocation (buybacks, capex, cash)** 4) **Legal / regulatory / risk factor map** 5) **Executive comp & governance** --- ## 1) What ISRG is (as described in filings): an “installed-base + recurring-consumables” ecosystem Intuitive positions itself as an ecosystem provider: systems + instruments/accessories + learning + services + “digital portfolio” (software/data) that together enable minimally invasive care. ["comprehensive ecosystem"](0001035267-25-000017|0) ### Core platforms (product stack) - **da Vinci** surgical systems span multiple generations including **da Vinci 5**, **X**, **Xi**, **SP**, plus older Si/S. ["fifth-generation da Vinci 5"](0001035267-25-000017|0) - **Ion** is Intuitive’s endoluminal (diagnostic) system, intended for minimally invasive lung biopsies; the company describes the catheter’s maneuverability and stability as key differentiators. ["Ion endoluminal system"](0001035267-25-000017|0) ### Business model in one sentence ISRG has a classic “razor/razorblade” profile: **place systems** (often via leases, including usage-based), then drive **recurring revenue** from instruments/accessories + services + operating-lease revenue as utilization grows. ["Operating lease revenue"](0001035267-25-000017|0) ["Total recurring revenue"](0001035267-25-000017|0) --- ## 2) Operating scale & growth: FY2024 baseline + FY2025 preliminary update ### FY2024 revenue mix (from 10-K) | Revenue (USD bn) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Instruments & accessories | 5.079 ["5,079.0"](0001035267-25-000017|0) | 4.277 ["4,276.6"](0001035267-25-000017|0) | 3.518 ["3,517.9"](0001035267-25-000017|0) | | Systems | 1.966 ["1,966.0"](0001035267-25-000017|0) | 1.680 ["1,679.7"](0001035267-25-000017|0) | 1.680 ["1,680.1"](0001035267-25-000017|0) | | Services | 1.307 ["1,307.1"](0001035267-25-000017|0) | 1.168 ["1,167.8"](0001035267-25-000017|0) | 1.024 ["1,024.2"](0001035267-25-000017|0) | | **Total revenue** | **8.352** ["8,352.1"](0001035267-25-000017|0) | **7.124** ["7,124.1"](0001035267-25-000017|0) | **6.222** ["6,222.2"](0001035267-25-000017|0) | | % recurring revenue | 84% ["% of Total revenue 84%"](0001035267-25-000017|0) | 83% ["% of Total revenue 83%"](0001035267-25-000017|0) | 79% ["% of Total revenue 79%"](0001035267-25-000017|0) | **Interpretation:** FY2024 growth is being driven most by **instruments & accessories** (procedure-linked) while systems + services also grew—consistent with a rising installed base and utilization. ["19% higher instruments"](0001035267-25-000017|0) ["12% higher service revenue"](0001035267-25-000017|0) ### Geography: still U.S.-heavy, but management explicitly expects OUS to rise over time | Geography (USD bn) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | U.S. revenue | 5.589 ["U.S. 5,589.4"](0001035267-25-000017|0) | 4.689 ["4,688.6"](0001035267-25-000017|0) | 4.158 ["4,157.6"](0001035267-25-000017|0) | | OUS revenue | 2.763 ["OUS 2,762.7"](0001035267-25-000017|0) | 2.436 ["2,435.5"](0001035267-25-000017|0) | 2.065 ["2,064.6"](0001035267-25-000017|0) | | Mix (U.S. / OUS) | 67% / 33% ["% of Revenue — U.S. 67%"](0001035267-25-000017|0) | 66% / 34% ["66%"](0001035267-25-000017|0) | 67% / 33% ["67%"](0001035267-25-000017|0) | Management frames OUS as a long-term growth lever (“expect … OUS … make up a greater portion”). ["OUS procedures and revenue"](0001035267-25-000017|0) --- ## 3) Profitability snapshot (GAAP) — what the P&L says (not what we hope) | (USD bn) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Total revenue | 8.352 ["Total revenue 8,352.1"](0001035267-25-000017|0) | 7.124 ["7,124.1"](0001035267-25-000017|0) | 6.222 ["6,222.2"](0001035267-25-000017|0) | | Gross profit | 5.634 ["Gross profit 5,634.2"](0001035267-25-000017|0) | 4.730 ["4,729.5"](0001035267-25-000017|0) | 4.196 ["4,196.0"](0001035267-25-000017|0) | | Operating income | 2.349 ["Income from operations 2,348.9"](0001035267-25-000017|0) | 1.767 ["1,766.8"](0001035267-25-000017|0) | 1.577 ["1,577.1"](0001035267-25-000017|0) | | Net income (attrib. to ISRG) | 2.323 ["Net income attributable… 2,322.6"](0001035267-25-000017|0) | 1.798 ["1,798.0"](0001035267-25-000017|0) | 1.322 ["1,322.3"](0001035267-25-000017|0) | | Diluted EPS (USD) | 6.42 ["Diluted 6.42"](0001035267-25-000017|0) | 5.03 ["5.03"](0001035267-25-000017|0) | 3.65 ["3.65"](0001035267-25-000017|0) | **What to watch analytically:** The company flags that gross margins can vary over time (and explicitly calls out margin variability as a risk). ["gross profit margins to vary"](0001035267-25-000099|0) --- ## 4) Installed base + procedures: the real “flywheel” Two reasons this matters more than near-term system shipments: 1) Instruments/accessories revenue scales with **procedures**. 2) Services scales with **installed base** (and utilization patterns). ### FY2024 system placements + recurring framing (10-K) | Metric | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | da Vinci placements (total) | 1,526 ["Total unit placements 1,526"](0001035267-25-000017|0) | 1,370 ["1,370"](0001035267-25-000017|0) | 1,264 ["1,264"](0001035267-25-000017|0) | | U.S. / OUS placements | 800 / 726 ["U.S. unit placements 800"](0001035267-25-000017|0) ["OUS unit placements 726"](0001035267-25-000017|0) | 666 / 704 ["666"](0001035267-25-000017|0) ["704"](0001035267-25-000017|0) | 692 / 572 ["692"](0001035267-25-000017|0) ["572"](0001035267-25-000017|0) | | Operating-lease placements (fixed / usage-based) | 309 / 467 ["fixed-payment… 309"](0001035267-25-000017|0) ["usage-based… 467"](0001035267-25-000017|0) | 304 / 355 ["304"](0001035267-25-000017|0) ["355"](0001035267-25-000017|0) | 276 / 216 ["276"](0001035267-25-000017|0) ["216"](0001035267-25-000017|0) | | Ion placements | 271 ["Ion System Placements 271"](0001035267-25-000017|0) | 213 ["213"](0001035267-25-000017|0) | 192 ["192"](0001035267-25-000017|0) | ### Ion installed base (10-K) — important because it signals “second flywheel” As of Dec 31, 2024, ISRG reports **805 Ion systems installed**, with **784 in the U.S.** ["installed base of 805 Ion"](0001035267-25-000017|0) ["784 of which"](0001035267-25-000017|0) ### FY2025 preliminary “state of the world” (8-K, Jan 14 2026) This is a major *disclosure update* because it includes **procedures, installed base, ASP, and I&A per procedure**—all in one table. | Metric | Q4 2025 | Q4 2024 | FY2025 | FY2024 | |---|---:|---:|---:|---:| | Total revenue (USD bn) | 2.866 ["2,866.2"](0001035267-26-000003|2) | 2.414 ["2,413.5"](0001035267-26-000003|2) | 10.065 ["10,064.7"](0001035267-26-000003|2) | 8.352 ["8,352.1"](0001035267-26-000003|2) | | da Vinci placements | 532 ["Total system placements 532"](0001035267-26-000003|2) | 493 ["493"](0001035267-26-000003|2) | 1,721 ["1,721"](0001035267-26-000003|2) | 1,526 ["1,526"](0001035267-26-000003|2) | | Ion placements | 42 ["Ion System Placements 42"](0001035267-26-000003|2) | 69 ["69"](0001035267-26-000003|2) | 195 ["195"](0001035267-26-000003|2) | 271 ["271"](0001035267-26-000003|2) | | da Vinci procedures (000s) | 849 ["Procedures (thousands) 849"](0001035267-26-000003|2) | 725 ["725"](0001035267-26-000003|2) | 3,153 ["3,153"](0001035267-26-000003|2) | 2,683 ["2,683"](0001035267-26-000003|2) | | Installed base | 11,106 ["Installed base… 11,106"](0001035267-26-000003|2) | 9,902 ["9,902"](0001035267-26-000003|2) | 11,106 ["11,106"](0001035267-26-000003|2) | 9,902 ["9,902"](0001035267-26-000003|2) | | I&A revenue / procedure (USD k) | 1.85 ["I&A revenue per procedure… 1.85"](0001035267-26-000003|2) | 1.86 ["1.86"](0001035267-26-000003|2) | 1.81 ["1.81"](0001035267-26-000003|2) | 1.81 ["1.81"](0001035267-26-000003|2) | | Avg selling price (USD m) | 1.68 ["Average Selling Price… 1.68"](0001035267-26-000003|2) | 1.59 ["1.59"](0001035267-26-000003|2) | 1.60 ["1.60"](0001035267-26-000003|2) | 1.50 ["1.50"](0001035267-26-000003|2) | **Two “tell me the truth” reads of the table:** - **Utilization flywheel remains strong:** procedures up and installed base up, while I&A per procedure is roughly flat (so growth is more volume-driven than price/mix). ["Procedures… 3,153"](0001035267-26-000003|2) ["I&A revenue per procedure"](0001035267-26-000003|2) - **Ion placements fell in FY2025 vs FY2024** (195 vs 271) even while the company states Ion procedures grew strongly (see next section). ["Ion System Placements… 195"](0001035267-26-000003|2) --- ## 5) Guidance / near-term expectations (from recent 8-K disclosures) In the Jan 14, 2026 8-K exhibit, the company states it **expects worldwide da Vinci procedures to increase ~13%–15% in 2026 vs 2025**. ["increase approximately 13% to 15%"](0001035267-26-000003|1) It also gives FY2025 preliminary procedure growth context: - FY2025 worldwide combined procedures (da Vinci + Ion) up ~19% vs 2024; da Vinci up ~18%, Ion up ~51%. ["Full year 2025… grew approximately 19%"](0001035267-26-000003|1) ["Ion procedures grew approximately 51%"](0001035267-26-000003|1) --- ## 6) Balance sheet strength & cash generation (where the “optionality” comes from) ### Balance sheet snapshot (10-K, USD bn unless noted) | Line item | Dec 31 2024 | Dec 31 2023 | |---|---:|---:| | Cash & cash equivalents | 2.027 ["Cash and cash equivalents… 2,027.4"](0001035267-25-000017|0) | 2.750 ["2,750.1"](0001035267-25-000017|0) | | Short-term investments | 1.986 ["Short-term investments 1,985.9"](0001035267-25-000017|0) | 2.473 ["2,473.1"](0001035267-25-000017|0) | | Long-term investments | 4.819 ["Long-term investments 4,819.1"](0001035267-25-000017|0) | 2.120 ["2,120.0"](0001035267-25-000017|0) | | **Total assets** | **18.743** ["Total assets 18,743.2"](0001035267-25-000017|0) | **15.442** ["15,441.5"](0001035267-25-000017|0) | | Total liabilities | 2.214 ["Total liabilities 2,213.6"](0001035267-25-000017|0) | 2.044 ["2,044.2"](0001035267-25-000017|0) | | Total stockholders’ equity | 16.530 ["Total stockholders’ equity 16,529.6"](0001035267-25-000017|0) | 13.397 ["13,397.3"](0001035267-25-000017|0) | The company also summarizes **cash, cash equivalents, and investments** at **$8.83B** as of Dec 31, 2024 (this matches the “cash + investments” framing, not just cash). ["$8.83 billion"](0001035267-25-000017|0) ### Cash flow table (10-K, USD bn) | (USD bn) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net cash from operating activities | 2.415 ["Operating activities… 2,415.0"](0001035267-25-000017|0) | 1.814 ["1,813.8"](0001035267-25-000017|0) | 1.491 ["1,490.8"](0001035267-25-000017|0) | | Net cash from investing activities | (3.273) ["Investing activities… (3,272.8)"](0001035267-25-000017|0) | (0.360) ["(360.1)"](0001035267-25-000017|0) | 1.371 ["1,370.8"](0001035267-25-000017|0) | | Net cash from financing activities | 0.151 ["Financing activities 150.9"](0001035267-25-000017|0) | (0.288) ["(287.6)"](0001035267-25-000017|0) | (2.572) ["(2,572.3)"](0001035267-25-000017|0) | A key FY2024 driver management highlights: inventory build and transfers tied to growth + leasing expansion + supply chain risk mitigation. ["expand our leasing business"](0001035267-25-000017|0) ["mitigate risks"](0001035267-25-000017|0) --- ## 7) Capital allocation: dividends vs buybacks - ISRG says it **has never declared or paid cash dividends** and intends to retain earnings (and may repurchase shares). ["never declared or paid"](0001035267-25-000017|0) - FY2024 quarter-end repurchase table shows **no repurchases in Q4 2024**, with **~$1.1B remaining authorization**. ["Total during quarter… —"](0001035267-25-000017|0) ["$ 1.1 billion"](0001035267-25-000017|0) Also, a later 8-K (Q3 2025 earnings release) notes **repurchase of 4.0M shares for $1.92B in Q3 2025**—useful context for how lumpy buybacks can be. ["repurchased 4.0 million shares"](0001035267-25-000206|1) --- ## 8) Risk map (what management highlights as “can break the model”) From the FY2024 10-K risk summary, the big buckets include: - **Competition / adoption risk** (customers may choose competitors or not accept robotic procedures). ["highly competitive"](0001035267-25-000099|0) - **Litigation / investigations** risk. ["litigation, investigations"](0001035267-25-000099|0) - **Supplier concentration / supply chain** risk. ["sole- and single-sourced"](0001035267-25-000099|0) - **Cybersecurity / IT failures** risk. ["cyberattacks"](0001035267-25-000099|0) - **Product defects / recalls** risk. ["recall"](0001035267-25-000099|0) - **Data privacy / AI regulatory** risk. ["artificial intelligence"](0001035267-25-000099|0) ["data privacy"](0001035267-25-000099|0) ### Litigation detail (how it actually shows up in disclosures) In the 10-Q legal proceedings section, the company describes: - ongoing **product liability** cases alleging injuries/death, defects, and/or inadequate training claims; the company disputes allegations and notes inability to estimate loss beyond accrual. ["product liability lawsuits"](0001035267-24-000247|0) ["unable to estimate"](0001035267-24-000247|0) - **antitrust-related** disputes in instruments/service/repair ecosystems (SIS case and consolidated class actions). ["antitrust claims"](0001035267-24-000247|0) ["In Re: da Vinci"](0001035267-24-000247|0) --- ## 9) Governance & executive compensation (proxy-driven highlights) From the 2025 proxy statement (covering 2024 compensation year): - It lists the 2024 **Named Executive Officers (NEOs)** including CEO Gary S. Guthart, CFO Jamie E. Samath, and President Dave Rosa. ["named executive officers"](0001035267-25-000098|0) - The proxy explicitly says the company does **not compensate the CEO or President for serving on the Board** beyond employee pay. ["We do not compensate"](0001035267-25-000098|0) (If you pick option **5** from the menu, I’ll extract and tabulate the **Summary Compensation Table** and key pay design elements from the proxy in the next turn.) --- ## 10) A practical “analyst lens” checklist for ISRG (grounded in disclosures) 1) **Procedure growth vs I&A per procedure:** volume is the primary driver; per-procedure I&A is disclosed and can be tracked. ["I&A revenue per procedure"](0001035267-26-000003|2) 2) **Mix shift to leasing/usage-based:** disclosed via placement splits; this can smooth adoption but changes revenue timing and working capital (inventory/capex). ["usage-based"](0001035267-25-000017|0) ["expand our leasing business"](0001035267-25-000017|0) 3) **da Vinci 5 ramp:** visible in placements by model in FY2025 preliminary table. ["da Vinci 5 Systems"](0001035267-26-000003|2) 4) **Ion trajectory:** placements can diverge from procedure growth; watch both. ["Ion procedures grew"](0001035267-26-000003|1) ["Ion System Placements"](0001035267-26-000003|2) 5) **Legal overhang:** product liability + antitrust themes recur in disclosures. ["product liability"](0001035267-24-000247|0) ["antitrust"](0001035267-24-000247|0) --- ### If you want the most “interactive” next step without you doing extra work: Reply with **1, 2, 3, 4, or 5** from the menu and I’ll expand that section with additional filing tables and tighter KPI math (computed), staying fully sourced.

## Intuitive Surgical (ISRG) — filing-driven deep dive (business, numbers, risks, governance) ### Quick “choose-your-own-adventure” menu (optional) Reply with a number anytime and I’ll extend that section further with more tables + excerpts: 1) **Unit economics / procedures / installed base** 2) **Margins & operating leverage** 3) **Capital allocation (buybacks, capex, cash)** 4) **Legal / regulatory / risk factor map** 5) **Executive comp & governance** --- ## 1) What ISRG is (as described in filings): an “installed-base + recurring-consumables” ecosystem Intuitive positions itself as an ecosystem provider: systems + instruments/accessories + learning + services + “digital portfolio” (software/data) that together enable minimally invasive care. ["comprehensive ecosystem"](0001035267-25-000017|0) ### Core platforms (product stack) - **da Vinci** surgical systems span multiple generations including **da Vinci 5**, **X**, **Xi**, **SP**, plus older Si/S. ["fifth-generation da Vinci 5"](0001035267-25-000017|0) - **Ion** is Intuitive’s endoluminal (diagnostic) system, intended for minimally invasive lung biopsies; the company describes the catheter’s maneuverability and stability as key differentiators. ["Ion endoluminal system"](0001035267-25-000017|0) ### Business model in one sentence ISRG has a classic “razor/razorblade” profile: **place systems** (often via leases, including usage-based), then drive **recurring revenue** from instruments/accessories + services + operating-lease revenue as utilization grows. ["Operating lease revenue"](0001035267-25-000017|0) ["Total recurring revenue"](0001035267-25-000017|0) --- ## 2) Operating scale & growth: FY2024 baseline + FY2025 preliminary update ### FY2024 revenue mix (from 10-K) | Revenue (USD bn) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Instruments & accessories | 5.079 ["5,079.0"](0001035267-25-000017|0) | 4.277 ["4,276.6"](0001035267-25-000017|0) | 3.518 ["3,517.9"](0001035267-25-000017|0) | | Systems | 1.966 ["1,966.0"](0001035267-25-000017|0) | 1.680 ["1,679.7"](0001035267-25-000017|0) | 1.680 ["1,680.1"](0001035267-25-000017|0) | | Services | 1.307 ["1,307.1"](0001035267-25-000017|0) | 1.168 ["1,167.8"](0001035267-25-000017|0) | 1.024 ["1,024.2"](0001035267-25-000017|0) | | **Total revenue** | **8.352** ["8,352.1"](0001035267-25-000017|0) | **7.124** ["7,124.1"](0001035267-25-000017|0) | **6.222** ["6,222.2"](0001035267-25-000017|0) | | % recurring revenue | 84% ["% of Total revenue 84%"](0001035267-25-000017|0) | 83% ["% of Total revenue 83%"](0001035267-25-000017|0) | 79% ["% of Total revenue 79%"](0001035267-25-000017|0) | **Interpretation:** FY2024 growth is being driven most by **instruments & accessories** (procedure-linked) while systems + services also grew—consistent with a rising installed base and utilization. ["19% higher instruments"](0001035267-25-000017|0) ["12% higher service revenue"](0001035267-25-000017|0) ### Geography: still U.S.-heavy, but management explicitly expects OUS to rise over time | Geography (USD bn) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | U.S. revenue | 5.589 ["U.S. 5,589.4"](0001035267-25-000017|0) | 4.689 ["4,688.6"](0001035267-25-000017|0) | 4.158 ["4,157.6"](0001035267-25-000017|0) | | OUS revenue | 2.763 ["OUS 2,762.7"](0001035267-25-000017|0) | 2.436 ["2,435.5"](0001035267-25-000017|0) | 2.065 ["2,064.6"](0001035267-25-000017|0) | | Mix (U.S. / OUS) | 67% / 33% ["% of Revenue — U.S. 67%"](0001035267-25-000017|0) | 66% / 34% ["66%"](0001035267-25-000017|0) | 67% / 33% ["67%"](0001035267-25-000017|0) | Management frames OUS as a long-term growth lever (“expect … OUS … make up a greater portion”). ["OUS procedures and revenue"](0001035267-25-000017|0) --- ## 3) Profitability snapshot (GAAP) — what the P&L says (not what we hope) | (USD bn) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Total revenue | 8.352 ["Total revenue 8,352.1"](0001035267-25-000017|0) | 7.124 ["7,124.1"](0001035267-25-000017|0) | 6.222 ["6,222.2"](0001035267-25-000017|0) | | Gross profit | 5.634 ["Gross profit 5,634.2"](0001035267-25-000017|0) | 4.730 ["4,729.5"](0001035267-25-000017|0) | 4.196 ["4,196.0"](0001035267-25-000017|0) | | Operating income | 2.349 ["Income from operations 2,348.9"](0001035267-25-000017|0) | 1.767 ["1,766.8"](0001035267-25-000017|0) | 1.577 ["1,577.1"](0001035267-25-000017|0) | | Net income (attrib. to ISRG) | 2.323 ["Net income attributable… 2,322.6"](0001035267-25-000017|0) | 1.798 ["1,798.0"](0001035267-25-000017|0) | 1.322 ["1,322.3"](0001035267-25-000017|0) | | Diluted EPS (USD) | 6.42 ["Diluted 6.42"](0001035267-25-000017|0) | 5.03 ["5.03"](0001035267-25-000017|0) | 3.65 ["3.65"](0001035267-25-000017|0) | **What to watch analytically:** The company flags that gross margins can vary over time (and explicitly calls out margin variability as a risk). ["gross profit margins to vary"](0001035267-25-000099|0) --- ## 4) Installed base + procedures: the real “flywheel” Two reasons this matters more than near-term system shipments: 1) Instruments/accessories revenue scales with **procedures**. 2) Services scales with **installed base** (and utilization patterns). ### FY2024 system placements + recurring framing (10-K) | Metric | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | da Vinci placements (total) | 1,526 ["Total unit placements 1,526"](0001035267-25-000017|0) | 1,370 ["1,370"](0001035267-25-000017|0) | 1,264 ["1,264"](0001035267-25-000017|0) | | U.S. / OUS placements | 800 / 726 ["U.S. unit placements 800"](0001035267-25-000017|0) ["OUS unit placements 726"](0001035267-25-000017|0) | 666 / 704 ["666"](0001035267-25-000017|0) ["704"](0001035267-25-000017|0) | 692 / 572 ["692"](0001035267-25-000017|0) ["572"](0001035267-25-000017|0) | | Operating-lease placements (fixed / usage-based) | 309 / 467 ["fixed-payment… 309"](0001035267-25-000017|0) ["usage-based… 467"](0001035267-25-000017|0) | 304 / 355 ["304"](0001035267-25-000017|0) ["355"](0001035267-25-000017|0) | 276 / 216 ["276"](0001035267-25-000017|0) ["216"](0001035267-25-000017|0) | | Ion placements | 271 ["Ion System Placements 271"](0001035267-25-000017|0) | 213 ["213"](0001035267-25-000017|0) | 192 ["192"](0001035267-25-000017|0) | ### Ion installed base (10-K) — important because it signals “second flywheel” As of Dec 31, 2024, ISRG reports **805 Ion systems installed**, with **784 in the U.S.** ["installed base of 805 Ion"](0001035267-25-000017|0) ["784 of which"](0001035267-25-000017|0) ### FY2025 preliminary “state of the world” (8-K, Jan 14 2026) This is a major *disclosure update* because it includes **procedures, installed base, ASP, and I&A per procedure**—all in one table. | Metric | Q4 2025 | Q4 2024 | FY2025 | FY2024 | |---|---:|---:|---:|---:| | Total revenue (USD bn) | 2.866 ["2,866.2"](0001035267-26-000003|2) | 2.414 ["2,413.5"](0001035267-26-000003|2) | 10.065 ["10,064.7"](0001035267-26-000003|2) | 8.352 ["8,352.1"](0001035267-26-000003|2) | | da Vinci placements | 532 ["Total system placements 532"](0001035267-26-000003|2) | 493 ["493"](0001035267-26-000003|2) | 1,721 ["1,721"](0001035267-26-000003|2) | 1,526 ["1,526"](0001035267-26-000003|2) | | Ion placements | 42 ["Ion System Placements 42"](0001035267-26-000003|2) | 69 ["69"](0001035267-26-000003|2) | 195 ["195"](0001035267-26-000003|2) | 271 ["271"](0001035267-26-000003|2) | | da Vinci procedures (000s) | 849 ["Procedures (thousands) 849"](0001035267-26-000003|2) | 725 ["725"](0001035267-26-000003|2) | 3,153 ["3,153"](0001035267-26-000003|2) | 2,683 ["2,683"](0001035267-26-000003|2) | | Installed base | 11,106 ["Installed base… 11,106"](0001035267-26-000003|2) | 9,902 ["9,902"](0001035267-26-000003|2) | 11,106 ["11,106"](0001035267-26-000003|2) | 9,902 ["9,902"](0001035267-26-000003|2) | | I&A revenue / procedure (USD k) | 1.85 ["I&A revenue per procedure… 1.85"](0001035267-26-000003|2) | 1.86 ["1.86"](0001035267-26-000003|2) | 1.81 ["1.81"](0001035267-26-000003|2) | 1.81 ["1.81"](0001035267-26-000003|2) | | Avg selling price (USD m) | 1.68 ["Average Selling Price… 1.68"](0001035267-26-000003|2) | 1.59 ["1.59"](0001035267-26-000003|2) | 1.60 ["1.60"](0001035267-26-000003|2) | 1.50 ["1.50"](0001035267-26-000003|2) | **Two “tell me the truth” reads of the table:** - **Utilization flywheel remains strong:** procedures up and installed base up, while I&A per procedure is roughly flat (so growth is more volume-driven than price/mix). ["Procedures… 3,153"](0001035267-26-000003|2) ["I&A revenue per procedure"](0001035267-26-000003|2) - **Ion placements fell in FY2025 vs FY2024** (195 vs 271) even while the company states Ion procedures grew strongly (see next section). ["Ion System Placements… 195"](0001035267-26-000003|2) --- ## 5) Guidance / near-term expectations (from recent 8-K disclosures) In the Jan 14, 2026 8-K exhibit, the company states it **expects worldwide da Vinci procedures to increase ~13%–15% in 2026 vs 2025**. ["increase approximately 13% to 15%"](0001035267-26-000003|1) It also gives FY2025 preliminary procedure growth context: - FY2025 worldwide combined procedures (da Vinci + Ion) up ~19% vs 2024; da Vinci up ~18%, Ion up ~51%. ["Full year 2025… grew approximately 19%"](0001035267-26-000003|1) ["Ion procedures grew approximately 51%"](0001035267-26-000003|1) --- ## 6) Balance sheet strength & cash generation (where the “optionality” comes from) ### Balance sheet snapshot (10-K, USD bn unless noted) | Line item | Dec 31 2024 | Dec 31 2023 | |---|---:|---:| | Cash & cash equivalents | 2.027 ["Cash and cash equivalents… 2,027.4"](0001035267-25-000017|0) | 2.750 ["2,750.1"](0001035267-25-000017|0) | | Short-term investments | 1.986 ["Short-term investments 1,985.9"](0001035267-25-000017|0) | 2.473 ["2,473.1"](0001035267-25-000017|0) | | Long-term investments | 4.819 ["Long-term investments 4,819.1"](0001035267-25-000017|0) | 2.120 ["2,120.0"](0001035267-25-000017|0) | | **Total assets** | **18.743** ["Total assets 18,743.2"](0001035267-25-000017|0) | **15.442** ["15,441.5"](0001035267-25-000017|0) | | Total liabilities | 2.214 ["Total liabilities 2,213.6"](0001035267-25-000017|0) | 2.044 ["2,044.2"](0001035267-25-000017|0) | | Total stockholders’ equity | 16.530 ["Total stockholders’ equity 16,529.6"](0001035267-25-000017|0) | 13.397 ["13,397.3"](0001035267-25-000017|0) | The company also summarizes **cash, cash equivalents, and investments** at **$8.83B** as of Dec 31, 2024 (this matches the “cash + investments” framing, not just cash). ["$8.83 billion"](0001035267-25-000017|0) ### Cash flow table (10-K, USD bn) | (USD bn) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net cash from operating activities | 2.415 ["Operating activities… 2,415.0"](0001035267-25-000017|0) | 1.814 ["1,813.8"](0001035267-25-000017|0) | 1.491 ["1,490.8"](0001035267-25-000017|0) | | Net cash from investing activities | (3.273) ["Investing activities… (3,272.8)"](0001035267-25-000017|0) | (0.360) ["(360.1)"](0001035267-25-000017|0) | 1.371 ["1,370.8"](0001035267-25-000017|0) | | Net cash from financing activities | 0.151 ["Financing activities 150.9"](0001035267-25-000017|0) | (0.288) ["(287.6)"](0001035267-25-000017|0) | (2.572) ["(2,572.3)"](0001035267-25-000017|0) | A key FY2024 driver management highlights: inventory build and transfers tied to growth + leasing expansion + supply chain risk mitigation. ["expand our leasing business"](0001035267-25-000017|0) ["mitigate risks"](0001035267-25-000017|0) --- ## 7) Capital allocation: dividends vs buybacks - ISRG says it **has never declared or paid cash dividends** and intends to retain earnings (and may repurchase shares). ["never declared or paid"](0001035267-25-000017|0) - FY2024 quarter-end repurchase table shows **no repurchases in Q4 2024**, with **~$1.1B remaining authorization**. ["Total during quarter… —"](0001035267-25-000017|0) ["$ 1.1 billion"](0001035267-25-000017|0) Also, a later 8-K (Q3 2025 earnings release) notes **repurchase of 4.0M shares for $1.92B in Q3 2025**—useful context for how lumpy buybacks can be. ["repurchased 4.0 million shares"](0001035267-25-000206|1) --- ## 8) Risk map (what management highlights as “can break the model”) From the FY2024 10-K risk summary, the big buckets include: - **Competition / adoption risk** (customers may choose competitors or not accept robotic procedures). ["highly competitive"](0001035267-25-000099|0) - **Litigation / investigations** risk. ["litigation, investigations"](0001035267-25-000099|0) - **Supplier concentration / supply chain** risk. ["sole- and single-sourced"](0001035267-25-000099|0) - **Cybersecurity / IT failures** risk. ["cyberattacks"](0001035267-25-000099|0) - **Product defects / recalls** risk. ["recall"](0001035267-25-000099|0) - **Data privacy / AI regulatory** risk. ["artificial intelligence"](0001035267-25-000099|0) ["data privacy"](0001035267-25-000099|0) ### Litigation detail (how it actually shows up in disclosures) In the 10-Q legal proceedings section, the company describes: - ongoing **product liability** cases alleging injuries/death, defects, and/or inadequate training claims; the company disputes allegations and notes inability to estimate loss beyond accrual. ["product liability lawsuits"](0001035267-24-000247|0) ["unable to estimate"](0001035267-24-000247|0) - **antitrust-related** disputes in instruments/service/repair ecosystems (SIS case and consolidated class actions). ["antitrust claims"](0001035267-24-000247|0) ["In Re: da Vinci"](0001035267-24-000247|0) --- ## 9) Governance & executive compensation (proxy-driven highlights) From the 2025 proxy statement (covering 2024 compensation year): - It lists the 2024 **Named Executive Officers (NEOs)** including CEO Gary S. Guthart, CFO Jamie E. Samath, and President Dave Rosa. ["named executive officers"](0001035267-25-000098|0) - The proxy explicitly says the company does **not compensate the CEO or President for serving on the Board** beyond employee pay. ["We do not compensate"](0001035267-25-000098|0) (If you pick option **5** from the menu, I’ll extract and tabulate the **Summary Compensation Table** and key pay design elements from the proxy in the next turn.) --- ## 10) A practical “analyst lens” checklist for ISRG (grounded in disclosures) 1) **Procedure growth vs I&A per procedure:** volume is the primary driver; per-procedure I&A is disclosed and can be tracked. ["I&A revenue per procedure"](0001035267-26-000003|2) 2) **Mix shift to leasing/usage-based:** disclosed via placement splits; this can smooth adoption but changes revenue timing and working capital (inventory/capex). ["usage-based"](0001035267-25-000017|0) ["expand our leasing business"](0001035267-25-000017|0) 3) **da Vinci 5 ramp:** visible in placements by model in FY2025 preliminary table. ["da Vinci 5 Systems"](0001035267-26-000003|2) 4) **Ion trajectory:** placements can diverge from procedure growth; watch both. ["Ion procedures grew"](0001035267-26-000003|1) ["Ion System Placements"](0001035267-26-000003|2) 5) **Legal overhang:** product liability + antitrust themes recur in disclosures. ["product liability"](0001035267-24-000247|0) ["antitrust"](0001035267-24-000247|0) --- ### If you want the most “interactive” next step without you doing extra work: Reply with **1, 2, 3, 4, or 5** from the menu and I’ll expand that section with additional filing tables and tighter KPI math (computed), staying fully sourced.